CETORNAN 5 g (ornithine), treatment of liver disease

Insufficient actual benefit as an adjuvant to nutrition in elderly undernourished subjects

• CETORNAN 5 g has Marketing Authorisation as an adjuvant to nutrition in elderly undernourished subjects
• In the absence, because of its ill-defined role in the therapeutic strategy, of clinical data that establish beyond doubt the efficacy of ornithine in the indication given in the Marketing Authorisation and in the opinion of experts, the actual benefit of CETORNAN 5 g and its generic equivalents is insufficient for reimbursement by National Health Insurance.